Melanoma Clinical Trial
Official title:
Melanoma Risk-Reduction Practices Among Melanoma Patients and Their Family Members
Primary Objectives:
- To conduct semi-structured interviews with melanoma patients and family members to
collect descriptive information on their UVR exposure, UVR exposure-reduction practices,
melanoma early detection practices, knowledge, psychosocial variables related to
melanoma risk-reduction (e.g., self-efficacy, norms, and expectations), and experiences
surrounding the diagnosis of melanoma in the family. Melanoma patients and family
members with children will be asked about the UVR exposure and UVR exposure-reduction
practices of their children, and parental practices to reduce UVR exposure among
children.
- To develop behavioral and attitudinal questionnaires based on data collected during
semi-structured interviews, and evaluate the appropriateness of these questionnaires
using cognitive interviewing techniques.
- To develop tailored messages aimed at promoting strategies to reduce UVR exposure (e.g.,
wearing protective clothing, minimizing midday UVR exposure, minimizing duration of UVR
exposure, using shade and sunscreen, avoiding sun lamps, and avoiding intentional
tanning) and improving adherence to surveillance and screening guidelines. Messages will
be developed to correspond to responses to questionnaire items.
- To assess tailored messages for their relevance, appropriateness, attractiveness and
appeal, credibility, and perceived behavioral impact among melanoma patients and their
family members.
Participants in Part 1 of the study will be asked to be interviewed about topics related to
melanoma risk-reduction, including opinions, attitudes, beliefs, and practices related to
ultraviolet radiation exposure, melanoma prevention, and melanoma detection.
Participants in Part 2 of the study will be asked to complete a written questionnaire on
melanoma risk-reduction and then be interviewed to obtain feedback on how the questionnaire
may be refined.
Participants in Part 3 of the study will be asked to be interviewed by telephone.
Participants then will receive educational material in the form of a newsletter tailored to
their interview responses. Participants then will be asked to be interviewed to obtain
feedback for refining the educational material. In each part of the study, the patient/family
member will receive a letter describing the study and the Consent Statement for Questionnaire
and Interview Studies.
Prior to the start of the interview, the Consent Statement will be read to the patient/family
member. Patients/family members may or may not choose to have the interview tape-recorded.
Participants may stop the interview or questionnaire at any time and may refuse to answer any
questions. At any time, the patient/family member may refuse to have the interview
tape-recorded. There is no treatment associated with this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|